XML 87 R41.htm IDEA: XBRL DOCUMENT
v3.21.1

Collaboration and License Arrangement with Genentech - Additional Information (Detail) | 12 Months Ended
--- | ---
Dec. 31, 2020 USD ($)
Collaboration And License Arrangement [Line Items] |
Collaboration revenue | $ 82,654,000
Contract asset | $ 7,654,000
Genentech [Member] | Genentech Agreement [Member] |
Collaboration And License Arrangement [Line Items] |
Collaborative arrangement, purpose | On December 11, 2020, the Company entered into the Genentech Agreement, which granted Genentech a license to develop and commercialize RLY-1971.
Collaborative arrangement, rights and obligations | Unless Genentech elects to exercise its option to conduct the remainder of the ongoing Phase 1a Trial, the Company is responsible for the completion of this trial. Genentech is responsible for conducting all subsequent clinical development of RLY-1971. The Company is also responsible for the one-time transfer of the active pharmaceutical ingredient (“API”) and other materials related to RLY-1971 to Genentech
Non-refundable upfront payment | $ 75,000,000
Milestone payment receivable | 25,000,000
Maximum additional amount received upon milestone achievement | 695,000,000
Collaboration agreement transaction price | 85,867,000
Non-refundable milestone payment transfer amount | 5,000,000
Non-refundable milestone payment for completion amount | 5,000,000
Variable consideration related to reimbursements due for research and development services | 867,000
Development based milestone payments under agreement | 0
Regulatory based milestone payments under agreement | 0
Genentech [Member] | Genentech Agreement [Member] | Transfer of License [Member] |
Collaboration And License Arrangement [Line Items] |
Collaboration revenue | 82,654,000
Genentech [Member] | Genentech Agreement [Member] | Research and Development Services [Member] |
Collaboration And License Arrangement [Line Items] |
Collaboration revenue | 0
Accounts receivable | 75,000,000
Genentech [Member] | Genentech Agreement [Member] | Transfer of Active Pharmaceutical Ingredients [Member] |
Collaboration And License Arrangement [Line Items] |
Collaboration revenue | 0
Contract asset | 7,654,000
Genentech [Member] | Genentech Agreement [Member] | Stand-alone Selling Prices (“SSP”) [Member] |
Collaboration And License Arrangement [Line Items] |
Collaboration agreement transaction price | 85,867,000
Genentech [Member] | Genentech Agreement [Member] | Stand-alone Selling Prices (“SSP”) [Member] | Transfer of License [Member] |
Collaboration And License Arrangement [Line Items] |
Remaining performance obligations | 82,654,000,000
Genentech [Member] | Genentech Agreement [Member] | Stand-alone Selling Prices (“SSP”) [Member] | Research and Development Services [Member] |
Collaboration And License Arrangement [Line Items] |
Remaining performance obligations | 2,896,000,000
Genentech [Member] | Genentech Agreement [Member] | Stand-alone Selling Prices (“SSP”) [Member] | Transfer of Active Pharmaceutical Ingredients [Member] |
Collaboration And License Arrangement [Line Items] |
Remaining performance obligations | 317,000,000
Genentech [Member] | Genentech Agreement [Member] | Outside US [Member] |
Collaboration And License Arrangement [Line Items] |
Maximum additional amount received upon milestone achievement | $ 410,000,000

X
- Definition Collaboration agreement transaction price. + References No definition available. + Details
Name: | rlay_CollaborationAgreementTransactionPrice
Namespace Prefix: | rlay_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration and license arrangement. + References No definition available. + Details
Name: | rlay_CollaborationAndLicenseArrangementLineItems
Namespace Prefix: | rlay_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Aggregate potential clinical development milestone payments available to be earned under a collaboration arrangement for each available target selected by the collaborator. + References No definition available. + Details
Name: | rlay_DevelopmentBasedMilestonePaymentsUnderAgreement
Namespace Prefix: | rlay_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Maximum additional amount received upon milestone achievement. + References No definition available. + Details
Name: | rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement
Namespace Prefix: | rlay_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payment receivable. + References No definition available. + Details
Name: | rlay_MilestonePaymentReceivable
Namespace Prefix: | rlay_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Non-refundable milestone for completion amount. + References No definition available. + Details
Name: | rlay_NonRefundableMilestoneForCompletionAmount
Namespace Prefix: | rlay_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Non-refundable milestone transfer amount. + References No definition available. + Details
Name: | rlay_NonRefundableMilestoneTransferAmount
Namespace Prefix: | rlay_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Non-refundable upfront payment. + References No definition available. + Details
Name: | rlay_NonRefundableUpfrontPayment
Namespace Prefix: | rlay_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Aggregate potential regulatory milestone payments available to be earned under a collaboration arrangement. + References No definition available. + Details
Name: | rlay_RegulatoryBasedMilestonePaymentsUnderAgreement
Namespace Prefix: | rlay_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Variable consideration related to reimbursements due for research and development services. + References No definition available. + Details
Name: | rlay_VariableConsiderationRelatedToReimbursementsDueForResearchAndDevelopmentServices
Namespace Prefix: | rlay_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(5)) -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910 + Details
Name: | us-gaap_AccountsReceivableNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Description of nature and purpose of collaborative arrangements. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_CollaborativeArrangementNatureAndPurpose
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of rights and obligations under the collaborative arrangements. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_CollaborativeArrangementRightsAndObligations
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044 + Details
Name: | us-gaap_ContractWithCustomerAssetNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | srt_CounterpartyNameAxis=rlay_GenentechIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rlay_GenentechAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rlay_LicenseAndTransferAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rlay_ResearchAndDevelopmentServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rlay_TransferOfActivePharmaceuticalIngredientsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rlay_StandAloneSellingPricesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |